EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Resistance to covalent Bruton's tyrosine kinase inhibitors in diffuse large B‑cell lymphoma: Molecular mechanisms and therapeutic implications (Review)

Chuanyang Lu, Tingting Zhou, Wenxin Zhang, Lulu Wei, Qiuni Chen, Yuye Shi, Chunling Wang, Liang Yu

International Journal of Oncology · 09.10.2026 · 69 (5) · 1-23

DOI: 10.3892/ijo.2026.5947 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Oncology, online erschienen am 09.10.2026. Verfasst von Chuanyang Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors, Drug Resistance, Neoplasm. Die Arbeit nennt 150 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B‑cell receptor (BCR) signaling is essential for the survival and proliferation of normal B cells, and contributes substantially to the pathogenesis of diffuse large B‑cell lymphoma (DLBCL). Bruton's tyrosine kinase (BTK), a key downstream component of the BCR pathway, has emerged as an important therapeutic target in B‑cell malignancies. However, the clinical efficacy of BTK inhibitors (BTKi) in DLBCL remains heterogeneous and is strongly influenced by molecular subtype and signaling dependency. Accumulating evidence indicates that BTKi resistance in DLBCL is driven by diverse molecular mechanisms, including BTK mutations, gain‑of‑function alterations in phospholipase Cγ2, activation of the caspase recruitment domain family member 11‑B‑cell lymphoma/leukemia 10‑mucosa‑associated lymphoid tissue lymphoma translocation protein 1 complex and dysregulation of myeloid differentiation primary response 88, cluster of differentiation 79B, tumor necrosis factor‑α‑induced protein 3 and Kelch‑like protein 14. In addition to these genetic determinants, non‑genetic adaptive mechanisms, such as compensatory phosphoinositide 3‑kinase/AKT/mechanistic target of rapamycin and mitogen‑activated protein kinase/extracellular signal‑-regulated kinase signaling, epigenetic reprogramming, tumor microenvironment remodeling, metabolic rewiring and endoplasmic reticulum stress, may further contribute to therapeutic escape. Emerging approaches, including next‑generation covalent and non‑covalent BTKi, dual‑mode inhibitors, BTK‑targeting degraders, allosteric inhibitors and multi‑target strategies, are currently being investigated as potential strategies to address BTKi resistance. The present review summarized the molecular mechanisms underlying BTKi resistance in DLBCL and discussed their potential implications for biomarker development, rational combination therapy and future precision treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAgammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsDrug Resistance, NeoplasmHumansSignal TransductionMutationAnimals

Stichwörter der Autor:innen

BTK inhibitorsBruton's tyrosine kinaseB‑cell receptor signalingNF‑κB signalingdiffuse large B‑cell lymphomadrug resistancemolecular subtypestargeted therapytumor microenvironment

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsBTK protein, human

Autor:innen und Institutionen

  • Department of Hematology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China.

Zitieren

APA

Lu, C., Zhou, T., Zhang, W., Wei, L., Chen, Q., Shi, Y., Wang, C., & Yu, L. (2026). Resistance to covalent Bruton's tyrosine kinase inhibitors in diffuse large B‑cell lymphoma: Molecular mechanisms and therapeutic implications (Review). International Journal of Oncology, 69(5), 1-23. https://doi.org/10.3892/ijo.2026.5947

Vancouver

Lu C, Zhou T, Zhang W, Wei L, Chen Q, Shi Y, et al. Resistance to covalent Bruton's tyrosine kinase inhibitors in diffuse large B‑cell lymphoma: Molecular mechanisms and therapeutic implications (Review). International Journal of Oncology. 2026;69(5):1-23. doi:10.3892/ijo.2026.5947

BibTeX
@article{Lu2026,
  author = {Lu, Chuanyang and Zhou, Tingting and Zhang, Wenxin and Wei, Lulu and Chen, Qiuni and Shi, Yuye and Wang, Chunling and Yu, Liang},
  title = {Resistance to covalent Bruton's tyrosine kinase inhibitors in diffuse large B‑cell lymphoma: Molecular mechanisms and therapeutic implications (Review)},
  journal = {International Journal of Oncology},
  year = {2026},
  volume = {69},
  number = {5},
  pages = {1--23},
  doi = {10.3892/ijo.2026.5947}
}
Kostenlos starten →